Protalix Biotherapeutics (NYSEAMERICAN:PLX) released its earnings results on Monday. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.12, Morningstar.com reports. The company had revenue of $27.02 million during the quarter, compared to analysts’ expectations of $10.45 million.
Shares of Protalix Biotherapeutics stock traded up $0.01 during trading on Tuesday, hitting $0.49. 1,491 shares of the company’s stock traded hands, compared to its average volume of 668,200. Protalix Biotherapeutics has a 1 year low of $0.27 and a 1 year high of $0.83.
Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC boosted its position in shares of Protalix Biotherapeutics by 44.4% during the fourth quarter. Virtu Financial LLC now owns 91,862 shares of the company’s stock valued at $29,000 after buying an additional 28,236 shares during the last quarter. Fosun International Ltd purchased a new stake in shares of Protalix Biotherapeutics during the third quarter valued at $1,881,000. Finally, Renaissance Technologies LLC boosted its position in shares of Protalix Biotherapeutics by 24.9% during the third quarter. Renaissance Technologies LLC now owns 3,266,401 shares of the company’s stock valued at $2,374,000 after buying an additional 651,701 shares during the last quarter.
PLX has been the topic of several recent analyst reports. Zacks Investment Research raised Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 21st. HC Wainwright set a $4.00 price objective on Protalix Biotherapeutics and gave the company a “buy” rating in a research report on Thursday, December 13th.
TRADEMARK VIOLATION WARNING: “Protalix Biotherapeutics (PLX) Releases Earnings Results, Beats Expectations By $0.12 EPS” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2019/03/19/protalix-biotherapeutics-plx-releases-earnings-results-beats-expectations-by-0-12-eps.html.
About Protalix Biotherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Featured Article: Do investors pay a separate front-end load every time they buy additional shares?
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.